Astra Zeneca

AstraZeneca reported a five-fold increase in net profit to $1.8 billion in Q1 2023, as sales of cancer treatments offset the slump in Covid-related treatments. The pharmaceutical giant’s turnover fell by 4% to US$10.9 billion, but excluding Covid-related sales, turnover jumped by 10% to $10.7 billion, with cancer treatment sales up 14%. AstraZeneca CEO Pascal Soriot credited the company’s strong start to the year to its impressive growth and innovation in emerging markets.